A Retrospective Study of Pneumococcal Pneumonia in Hospitalized Patients Aged ≥65 Years in Izumo, Japan: 2010 to 2014

被引:0
|
作者
Hamaguchi, Megumi [1 ,5 ]
Tsubata, Yukari [1 ]
Yoshihara, Ken [1 ]
Nakao, Mika [1 ]
Amano, Yoshihiro [1 ]
Nakashima, Kazuhisa [1 ]
Hotta, Takamasa [2 ]
Okimoto, Tamio [1 ]
Hamaguchi, Shunichi [3 ]
Sutani, Akihisa [4 ]
Isobe, Takeshi [1 ]
机构
[1] Shimane Univ, Dept Internal Med, Div Med Oncol & Resp Med, Izumo, Shimane, Japan
[2] Shimane Prefectural Cent Hosp, Dept Resp Med, Izumo, Shimane, Japan
[3] Shimane Univ, Dept Gen Med, Izumo, Shimane, Japan
[4] Sutani Resp Clin, Izumo, Shimane, Japan
[5] Shimane Univ, Dept Internal Med, Div Med Oncol & Resp Med, 89-1,Enyacho, Izumo, Shimane, Japan
关键词
Streptococcus pneumoniae; pneumococcal pneumonia; vaccine; PPSV23; PCV13; POLYSACCHARIDE VACCINE; ADULTS; MORTALITY; IMPACT;
D O I
10.2147/IJGM.S407732
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: In Japan, both a 23-valent pneumococcal polysaccharide vaccine (PPSV23) and a 13-valent pneumococcal conjugate vaccine (PCV13) are available. Although randomized controlled trials have examined the effects of pneumococcal vaccines, few epidemiological studies have investigated the onset of pneumococcal pneumonia in general practice. In Izumo, Shimane Prefecture, Japan, a public subsidy for PPSV23 inoculation began in November 2012.Patients and Methods: The subjects were pneumonia patients aged 65 and over who were admitted to a hospital in Izumo. This retrospective study analyzed the following data extracted from medical records: pneumococcal pneumonia prevalence, pneumonia severity, mortality rate, PPSV23 vaccination rate, and length of hospital stay. The 2 years before the start of the public subsidy were defined as the early phase, and the 2 years after the subsidy initiation were defined as the late phase. We compared the two phases in terms of PPSV23 vaccination rate, prevalence and severity of pneumococcal pneumonia, and mortality rate.Results: We investigated data from a total of 1188 and 1086 patients in the early and late phases, respectively. The prevalence of pneumococcal pneumonia was 21.0% and 21.3% in the early and late phases, respectively. The mortality rate from pneumococcal pneumonia was 10.4% and 5.4% in the early and late phases, respectively (p = 0.080), indicating a 50% reduction. The PPSV23 vaccination rate (p < 0.001) and the comorbidity rates of chronic respiratory disease (p = 0.022) and chronic renal disease (p < 0.001) were significantly different between the early and late phases. Conclusion: This study showed that the rate of in-hospital deaths due to pneumococcal pneumonia was halved after the PPSV23 vaccine was subsidized. The causal relationship between the pneumococcal vaccination rate and the mortality rate of pneumococcal disease was unclear. Further investigation is deemed necessary.
引用
下载
收藏
页码:2125 / 2132
页数:8
相关论文
共 50 条
  • [1] Effect of Sarcopenia on Pneumonia after Endoscopic Submucosal Resection in Patients Aged ≥65 Years: A Retrospective Study
    Kim, Min-Yu
    Kim, So Yeon
    Shin, Hye Jung
    Kweon, Ki Hong
    Park, Jooeun
    Kim, Na Young
    CANCERS, 2023, 15 (19)
  • [2] Factors associated with pneumococcal and influenza vaccination in hospitalized people aged ≥65 years
    Sintes, X.
    Nebot, M.
    Izquierdo, C.
    Ruiz, L.
    Dominguez, A.
    Bayas, J. M.
    Vera, I.
    Carratala, J.
    Sousa, D.
    EPIDEMIOLOGY AND INFECTION, 2011, 139 (05): : 666 - 673
  • [3] ICD-10 codes are a valid tool for identification of pneumonia in hospitalized patients aged ≥65 years
    Skull, S. A.
    Andrews, R. M.
    Byrnes, G. B.
    Campbell, D. A.
    Nolan, T. M.
    Brown, G. V.
    Kelly, H. A.
    EPIDEMIOLOGY AND INFECTION, 2008, 136 (02): : 232 - 240
  • [4] Pneumococcal bacteremia in patients aged over 65 years. A study of 161 cases
    Subirats, MV
    Valero, MS
    Creus, BF
    Sanmiguel, GS
    Aymerich, DF
    Porta, FS
    MEDICINA CLINICA, 2001, 117 (07): : 241 - 245
  • [5] Effect of the 23-valent pneumococcal polysaccharide vaccine on the incidence of hospitalization with pneumonia in adults aged ≥65 years: retrospective cohort study using a population-based database in Japan
    Yamana, Hayato
    Ono, Sachiko
    Michihata, Nobuaki
    Uemura, Kohei
    Jo, Taisuke
    Yasunaga, Hideo
    CLINICAL MICROBIOLOGY AND INFECTION, 2023, 29 (07) : 904 - 910
  • [6] Association of Pneumococcal Conjugate Vaccine Use With Hospitalized Pneumonia in Medicare Beneficiaries 65 Years or Older With and Without Medical Conditions, 2014 to 2017
    Kobayashi, Miwako
    Spiller, Michael W.
    Wu, Xiyuan
    Wang, Rongrong
    Chillarige, Yoganand
    Wernecke, Michael
    MaCurdy, Thomas E.
    Kelman, Jeffery A.
    Deng, Li
    Shang, Nong
    Whitney, Cynthia G.
    Pilishvili, Tamara
    Lessa, Fernanda C.
    JAMA INTERNAL MEDICINE, 2023, 183 (01) : 40 - 47
  • [7] The Relationship Between Pneumococcal Vaccination and Pneumonia in Hospitalized Older Adult Patients in Japan
    Fukuda, N.
    Keisuke, W.
    Nobuyuki, H.
    Yuu, H.
    Nobuaki, K.
    Takeshi, K.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [8] Baseline clinical characteristics and prognostic factors in hospitalized COVID-19 patients aged ≤ 65 years: A retrospective observational study
    Betti, Marta
    Bertolotti, Marinella
    Ferrante, Daniela
    Roveta, Annalisa
    Pelazza, Carolina
    Giacchero, Fabio
    Penpa, Serena
    Massarino, Costanza
    Bolgeo, Tatiana
    Cassinari, Antonella
    Mussa, Marco
    Chichino, Guido
    Maconi, Antonio
    PLOS ONE, 2021, 16 (03):
  • [9] BARIATRIC SURGERY OUTCOMES IN PATIENTS AGED 65 YEARS AND OLDER: 3 YEARS RETROSPECTIVE STUDY
    Kr, M.
    Narwaria, M.
    Patolia, S.
    Mittal, D.
    Murugan, B.
    Jayachandran, A.
    OBESITY SURGERY, 2018, 28 : 276 - 276
  • [10] Incremental effectiveness of pneumococcal vaccine on simultaneously administered influenza vaccine in preventing pneumonia and pneumococcal pneumonia among persons aged 65 years or older
    Honkanen, PO
    Keistinen, T
    Miettinen, L
    Herva, E
    Sankilampi, U
    Läärä, E
    Leinonen, M
    Kivelä, SL
    Mäkela, PH
    VACCINE, 1999, 17 (20-21) : 2493 - 2500